AstraZeneca's Lynparza OK'd in Europe for BRCA+ pancreatic cancer

• The European Commission has approved AstraZeneca's (NYSE:AZN) PARP inhibitor Lynparza (olaparib) for the treatment of patients with germline BRCA-mutated metastatic pancreatic cancer.
• About 5-7% of metastatic pancreatic cancer patients have such a germline mutation.
• Lynparza is approved in the U.S. and several other countries as first-line maintenance treatment for these patients.
• Shares up a fraction premarket.